A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em<

As one of the first families of marine natural products to undergo clinical trials, the didemnin depsipeptides have played a significant role in inspiring the discovery of marine drugs. Originally developed as anticancer therapeutics, the recent re-evaluation of these compounds including synthetical...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Robert J. Stankey [verfasserIn] Don Johnson [verfasserIn] Brendan M. Duggan [verfasserIn] David A. Mead [verfasserIn] James J. La Clair [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	didemnin depsipeptide non–ribosomal peptide biosynthesis metabolomics

Übergeordnetes Werk:	In: Marine Drugs - MDPI AG, 2005, 21(2023), 2, p 56
Übergeordnetes Werk:	volume:21 ; year:2023 ; number:2, p 56

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/md21020056

Katalog-ID:	DOAJ080226639

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ080226639
003	DE-627
005	20240413062450.0
007	cr uuu---uuuuu
008	230310s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/md21020056 \|2 doi
035			\|a (DE-627)DOAJ080226639
035			\|a (DE-599)DOAJef827ce5676c4de0a82d59de9de787c0
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a QH301-705.5
100	0		\|a Robert J. Stankey \|e verfasserin \|4 aut
245	1	2	\|a A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em<
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a As one of the first families of marine natural products to undergo clinical trials, the didemnin depsipeptides have played a significant role in inspiring the discovery of marine drugs. Originally developed as anticancer therapeutics, the recent re-evaluation of these compounds including synthetically derived dehydrodidemnin B or Aplidine, has led to their advancement towards antiviral applications. While conventionally associated with production in colonial tunicates of the family <i<Didemnidae</i<, recent studies have identified their biosynthetic gene clusters from the marine–derived bacteria <i<Tistrella mobilis</i<. While these studies confirm the production of didemnin X/Y, the low titer and general lack of understanding of their biosynthesis in <i<Tistrella</i< currently prevents the development of effective microbial or synthetic biological approaches for their production. To this end, we conducted a survey of known species of <i<Tistrella</i< and report on their ability to produce the didemnin depsipeptides. These data were used to develop conditions to produce didemnin B at titers over 15 mg/L.
650		4	\|a didemnin
650		4	\|a depsipeptide
650		4	\|a non–ribosomal peptide
650		4	\|a biosynthesis
650		4	\|a metabolomics
653		0	\|a Biology (General)
700	0		\|a Don Johnson \|e verfasserin \|4 aut
700	0		\|a Brendan M. Duggan \|e verfasserin \|4 aut
700	0		\|a David A. Mead \|e verfasserin \|4 aut
700	0		\|a James J. La Clair \|e verfasserin \|4 aut
773	0	8	\|i In \|t Marine Drugs \|d MDPI AG, 2005 \|g 21(2023), 2, p 56 \|w (DE-627)477992420 \|w (DE-600)2175190-0 \|x 16603397 \|7 nnns
773	1	8	\|g volume:21 \|g year:2023 \|g number:2, p 56
856	4	0	\|u https://doi.org/10.3390/md21020056 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/ef827ce5676c4de0a82d59de9de787c0 \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/1660-3397/21/2/56 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1660-3397 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_381
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 21 \|j 2023 \|e 2, p 56

Indexfelder

author_variant	r j s rjs d j dj b m d bmd d a m dam j j l c jjlc
matchkey_str	article:16603397:2023----::sreoddmidpietdpouto
hierarchy_sort_str	2023
callnumber-subject-code	QH
publishDate	2023
allfields	10.3390/md21020056 doi (DE-627)DOAJ080226639 (DE-599)DOAJef827ce5676c4de0a82d59de9de787c0 DE-627 ger DE-627 rakwb eng QH301-705.5 Robert J. Stankey verfasserin aut A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em< 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier As one of the first families of marine natural products to undergo clinical trials, the didemnin depsipeptides have played a significant role in inspiring the discovery of marine drugs. Originally developed as anticancer therapeutics, the recent re-evaluation of these compounds including synthetically derived dehydrodidemnin B or Aplidine, has led to their advancement towards antiviral applications. While conventionally associated with production in colonial tunicates of the family <i<Didemnidae</i<, recent studies have identified their biosynthetic gene clusters from the marine–derived bacteria <i<Tistrella mobilis</i<. While these studies confirm the production of didemnin X/Y, the low titer and general lack of understanding of their biosynthesis in <i<Tistrella</i< currently prevents the development of effective microbial or synthetic biological approaches for their production. To this end, we conducted a survey of known species of <i<Tistrella</i< and report on their ability to produce the didemnin depsipeptides. These data were used to develop conditions to produce didemnin B at titers over 15 mg/L. didemnin depsipeptide non–ribosomal peptide biosynthesis metabolomics Biology (General) Don Johnson verfasserin aut Brendan M. Duggan verfasserin aut David A. Mead verfasserin aut James J. La Clair verfasserin aut In Marine Drugs MDPI AG, 2005 21(2023), 2, p 56 (DE-627)477992420 (DE-600)2175190-0 16603397 nnns volume:21 year:2023 number:2, p 56 https://doi.org/10.3390/md21020056 kostenfrei https://doaj.org/article/ef827ce5676c4de0a82d59de9de787c0 kostenfrei https://www.mdpi.com/1660-3397/21/2/56 kostenfrei https://doaj.org/toc/1660-3397 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_381 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 21 2023 2, p 56
spelling	10.3390/md21020056 doi (DE-627)DOAJ080226639 (DE-599)DOAJef827ce5676c4de0a82d59de9de787c0 DE-627 ger DE-627 rakwb eng QH301-705.5 Robert J. Stankey verfasserin aut A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em< 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier As one of the first families of marine natural products to undergo clinical trials, the didemnin depsipeptides have played a significant role in inspiring the discovery of marine drugs. Originally developed as anticancer therapeutics, the recent re-evaluation of these compounds including synthetically derived dehydrodidemnin B or Aplidine, has led to their advancement towards antiviral applications. While conventionally associated with production in colonial tunicates of the family <i<Didemnidae</i<, recent studies have identified their biosynthetic gene clusters from the marine–derived bacteria <i<Tistrella mobilis</i<. While these studies confirm the production of didemnin X/Y, the low titer and general lack of understanding of their biosynthesis in <i<Tistrella</i< currently prevents the development of effective microbial or synthetic biological approaches for their production. To this end, we conducted a survey of known species of <i<Tistrella</i< and report on their ability to produce the didemnin depsipeptides. These data were used to develop conditions to produce didemnin B at titers over 15 mg/L. didemnin depsipeptide non–ribosomal peptide biosynthesis metabolomics Biology (General) Don Johnson verfasserin aut Brendan M. Duggan verfasserin aut David A. Mead verfasserin aut James J. La Clair verfasserin aut In Marine Drugs MDPI AG, 2005 21(2023), 2, p 56 (DE-627)477992420 (DE-600)2175190-0 16603397 nnns volume:21 year:2023 number:2, p 56 https://doi.org/10.3390/md21020056 kostenfrei https://doaj.org/article/ef827ce5676c4de0a82d59de9de787c0 kostenfrei https://www.mdpi.com/1660-3397/21/2/56 kostenfrei https://doaj.org/toc/1660-3397 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_381 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 21 2023 2, p 56
allfields_unstemmed	10.3390/md21020056 doi (DE-627)DOAJ080226639 (DE-599)DOAJef827ce5676c4de0a82d59de9de787c0 DE-627 ger DE-627 rakwb eng QH301-705.5 Robert J. Stankey verfasserin aut A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em< 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier As one of the first families of marine natural products to undergo clinical trials, the didemnin depsipeptides have played a significant role in inspiring the discovery of marine drugs. Originally developed as anticancer therapeutics, the recent re-evaluation of these compounds including synthetically derived dehydrodidemnin B or Aplidine, has led to their advancement towards antiviral applications. While conventionally associated with production in colonial tunicates of the family <i<Didemnidae</i<, recent studies have identified their biosynthetic gene clusters from the marine–derived bacteria <i<Tistrella mobilis</i<. While these studies confirm the production of didemnin X/Y, the low titer and general lack of understanding of their biosynthesis in <i<Tistrella</i< currently prevents the development of effective microbial or synthetic biological approaches for their production. To this end, we conducted a survey of known species of <i<Tistrella</i< and report on their ability to produce the didemnin depsipeptides. These data were used to develop conditions to produce didemnin B at titers over 15 mg/L. didemnin depsipeptide non–ribosomal peptide biosynthesis metabolomics Biology (General) Don Johnson verfasserin aut Brendan M. Duggan verfasserin aut David A. Mead verfasserin aut James J. La Clair verfasserin aut In Marine Drugs MDPI AG, 2005 21(2023), 2, p 56 (DE-627)477992420 (DE-600)2175190-0 16603397 nnns volume:21 year:2023 number:2, p 56 https://doi.org/10.3390/md21020056 kostenfrei https://doaj.org/article/ef827ce5676c4de0a82d59de9de787c0 kostenfrei https://www.mdpi.com/1660-3397/21/2/56 kostenfrei https://doaj.org/toc/1660-3397 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_381 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 21 2023 2, p 56
allfieldsGer	10.3390/md21020056 doi (DE-627)DOAJ080226639 (DE-599)DOAJef827ce5676c4de0a82d59de9de787c0 DE-627 ger DE-627 rakwb eng QH301-705.5 Robert J. Stankey verfasserin aut A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em< 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier As one of the first families of marine natural products to undergo clinical trials, the didemnin depsipeptides have played a significant role in inspiring the discovery of marine drugs. Originally developed as anticancer therapeutics, the recent re-evaluation of these compounds including synthetically derived dehydrodidemnin B or Aplidine, has led to their advancement towards antiviral applications. While conventionally associated with production in colonial tunicates of the family <i<Didemnidae</i<, recent studies have identified their biosynthetic gene clusters from the marine–derived bacteria <i<Tistrella mobilis</i<. While these studies confirm the production of didemnin X/Y, the low titer and general lack of understanding of their biosynthesis in <i<Tistrella</i< currently prevents the development of effective microbial or synthetic biological approaches for their production. To this end, we conducted a survey of known species of <i<Tistrella</i< and report on their ability to produce the didemnin depsipeptides. These data were used to develop conditions to produce didemnin B at titers over 15 mg/L. didemnin depsipeptide non–ribosomal peptide biosynthesis metabolomics Biology (General) Don Johnson verfasserin aut Brendan M. Duggan verfasserin aut David A. Mead verfasserin aut James J. La Clair verfasserin aut In Marine Drugs MDPI AG, 2005 21(2023), 2, p 56 (DE-627)477992420 (DE-600)2175190-0 16603397 nnns volume:21 year:2023 number:2, p 56 https://doi.org/10.3390/md21020056 kostenfrei https://doaj.org/article/ef827ce5676c4de0a82d59de9de787c0 kostenfrei https://www.mdpi.com/1660-3397/21/2/56 kostenfrei https://doaj.org/toc/1660-3397 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_381 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 21 2023 2, p 56
allfieldsSound	10.3390/md21020056 doi (DE-627)DOAJ080226639 (DE-599)DOAJef827ce5676c4de0a82d59de9de787c0 DE-627 ger DE-627 rakwb eng QH301-705.5 Robert J. Stankey verfasserin aut A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em< 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier As one of the first families of marine natural products to undergo clinical trials, the didemnin depsipeptides have played a significant role in inspiring the discovery of marine drugs. Originally developed as anticancer therapeutics, the recent re-evaluation of these compounds including synthetically derived dehydrodidemnin B or Aplidine, has led to their advancement towards antiviral applications. While conventionally associated with production in colonial tunicates of the family <i<Didemnidae</i<, recent studies have identified their biosynthetic gene clusters from the marine–derived bacteria <i<Tistrella mobilis</i<. While these studies confirm the production of didemnin X/Y, the low titer and general lack of understanding of their biosynthesis in <i<Tistrella</i< currently prevents the development of effective microbial or synthetic biological approaches for their production. To this end, we conducted a survey of known species of <i<Tistrella</i< and report on their ability to produce the didemnin depsipeptides. These data were used to develop conditions to produce didemnin B at titers over 15 mg/L. didemnin depsipeptide non–ribosomal peptide biosynthesis metabolomics Biology (General) Don Johnson verfasserin aut Brendan M. Duggan verfasserin aut David A. Mead verfasserin aut James J. La Clair verfasserin aut In Marine Drugs MDPI AG, 2005 21(2023), 2, p 56 (DE-627)477992420 (DE-600)2175190-0 16603397 nnns volume:21 year:2023 number:2, p 56 https://doi.org/10.3390/md21020056 kostenfrei https://doaj.org/article/ef827ce5676c4de0a82d59de9de787c0 kostenfrei https://www.mdpi.com/1660-3397/21/2/56 kostenfrei https://doaj.org/toc/1660-3397 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_381 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 21 2023 2, p 56
language	English
source	In Marine Drugs 21(2023), 2, p 56 volume:21 year:2023 number:2, p 56
sourceStr	In Marine Drugs 21(2023), 2, p 56 volume:21 year:2023 number:2, p 56
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	didemnin depsipeptide non–ribosomal peptide biosynthesis metabolomics Biology (General)
isfreeaccess_bool	true
container_title	Marine Drugs
authorswithroles_txt_mv	Robert J. Stankey @@aut@@ Don Johnson @@aut@@ Brendan M. Duggan @@aut@@ David A. Mead @@aut@@ James J. La Clair @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	477992420
id	DOAJ080226639
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ080226639</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413062450.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230310s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/md21020056</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ080226639</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJef827ce5676c4de0a82d59de9de787c0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH301-705.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Robert J. Stankey</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em<</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">As one of the first families of marine natural products to undergo clinical trials, the didemnin depsipeptides have played a significant role in inspiring the discovery of marine drugs. Originally developed as anticancer therapeutics, the recent re-evaluation of these compounds including synthetically derived dehydrodidemnin B or Aplidine, has led to their advancement towards antiviral applications. While conventionally associated with production in colonial tunicates of the family <i<Didemnidae</i<, recent studies have identified their biosynthetic gene clusters from the marine–derived bacteria <i<Tistrella mobilis</i<. While these studies confirm the production of didemnin X/Y, the low titer and general lack of understanding of their biosynthesis in <i<Tistrella</i< currently prevents the development of effective microbial or synthetic biological approaches for their production. To this end, we conducted a survey of known species of <i<Tistrella</i< and report on their ability to produce the didemnin depsipeptides. These data were used to develop conditions to produce didemnin B at titers over 15 mg/L.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">didemnin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">depsipeptide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">non–ribosomal peptide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biosynthesis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">metabolomics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Biology (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Don Johnson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Brendan M. Duggan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David A. Mead</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">James J. La Clair</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Marine Drugs</subfield><subfield code="d">MDPI AG, 2005</subfield><subfield code="g">21(2023), 2, p 56</subfield><subfield code="w">(DE-627)477992420</subfield><subfield code="w">(DE-600)2175190-0</subfield><subfield code="x">16603397</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:21</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:2, p 56</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/md21020056</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ef827ce5676c4de0a82d59de9de787c0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/1660-3397/21/2/56</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1660-3397</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_381</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">21</subfield><subfield code="j">2023</subfield><subfield code="e">2, p 56</subfield></datafield></record></collection>
callnumber-first	Q - Science
author	Robert J. Stankey
spellingShingle	Robert J. Stankey misc QH301-705.5 misc didemnin misc depsipeptide misc non–ribosomal peptide misc biosynthesis misc metabolomics misc Biology (General) A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em<
authorStr	Robert J. Stankey
ppnlink_with_tag_str_mv	@@773@@(DE-627)477992420
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	QH301-705
illustrated	Not Illustrated
issn	16603397
topic_title	QH301-705.5 A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em< didemnin depsipeptide non–ribosomal peptide biosynthesis metabolomics
topic	misc QH301-705.5 misc didemnin misc depsipeptide misc non–ribosomal peptide misc biosynthesis misc metabolomics misc Biology (General)
topic_unstemmed	misc QH301-705.5 misc didemnin misc depsipeptide misc non–ribosomal peptide misc biosynthesis misc metabolomics misc Biology (General)
topic_browse	misc QH301-705.5 misc didemnin misc depsipeptide misc non–ribosomal peptide misc biosynthesis misc metabolomics misc Biology (General)
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Marine Drugs
hierarchy_parent_id	477992420
hierarchy_top_title	Marine Drugs
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)477992420 (DE-600)2175190-0
title	A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em<
ctrlnum	(DE-627)DOAJ080226639 (DE-599)DOAJef827ce5676c4de0a82d59de9de787c0
title_full	A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em<
author_sort	Robert J. Stankey
journal	Marine Drugs
journalStr	Marine Drugs
callnumber-first-code	Q
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
author_browse	Robert J. Stankey Don Johnson Brendan M. Duggan David A. Mead James J. La Clair
container_volume	21
class	QH301-705.5
format_se	Elektronische Aufsätze
author-letter	Robert J. Stankey
doi_str_mv	10.3390/md21020056
author2-role	verfasserin
title_sort	survey of didemnin depsipeptide production in <em<tistrella</em<
callnumber	QH301-705.5
title_auth	A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em<
abstract	As one of the first families of marine natural products to undergo clinical trials, the didemnin depsipeptides have played a significant role in inspiring the discovery of marine drugs. Originally developed as anticancer therapeutics, the recent re-evaluation of these compounds including synthetically derived dehydrodidemnin B or Aplidine, has led to their advancement towards antiviral applications. While conventionally associated with production in colonial tunicates of the family <i<Didemnidae</i<, recent studies have identified their biosynthetic gene clusters from the marine–derived bacteria <i<Tistrella mobilis</i<. While these studies confirm the production of didemnin X/Y, the low titer and general lack of understanding of their biosynthesis in <i<Tistrella</i< currently prevents the development of effective microbial or synthetic biological approaches for their production. To this end, we conducted a survey of known species of <i<Tistrella</i< and report on their ability to produce the didemnin depsipeptides. These data were used to develop conditions to produce didemnin B at titers over 15 mg/L.
abstractGer	As one of the first families of marine natural products to undergo clinical trials, the didemnin depsipeptides have played a significant role in inspiring the discovery of marine drugs. Originally developed as anticancer therapeutics, the recent re-evaluation of these compounds including synthetically derived dehydrodidemnin B or Aplidine, has led to their advancement towards antiviral applications. While conventionally associated with production in colonial tunicates of the family <i<Didemnidae</i<, recent studies have identified their biosynthetic gene clusters from the marine–derived bacteria <i<Tistrella mobilis</i<. While these studies confirm the production of didemnin X/Y, the low titer and general lack of understanding of their biosynthesis in <i<Tistrella</i< currently prevents the development of effective microbial or synthetic biological approaches for their production. To this end, we conducted a survey of known species of <i<Tistrella</i< and report on their ability to produce the didemnin depsipeptides. These data were used to develop conditions to produce didemnin B at titers over 15 mg/L.
abstract_unstemmed	As one of the first families of marine natural products to undergo clinical trials, the didemnin depsipeptides have played a significant role in inspiring the discovery of marine drugs. Originally developed as anticancer therapeutics, the recent re-evaluation of these compounds including synthetically derived dehydrodidemnin B or Aplidine, has led to their advancement towards antiviral applications. While conventionally associated with production in colonial tunicates of the family <i<Didemnidae</i<, recent studies have identified their biosynthetic gene clusters from the marine–derived bacteria <i<Tistrella mobilis</i<. While these studies confirm the production of didemnin X/Y, the low titer and general lack of understanding of their biosynthesis in <i<Tistrella</i< currently prevents the development of effective microbial or synthetic biological approaches for their production. To this end, we conducted a survey of known species of <i<Tistrella</i< and report on their ability to produce the didemnin depsipeptides. These data were used to develop conditions to produce didemnin B at titers over 15 mg/L.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_381 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2, p 56
title_short	A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em<
url	https://doi.org/10.3390/md21020056 https://doaj.org/article/ef827ce5676c4de0a82d59de9de787c0 https://www.mdpi.com/1660-3397/21/2/56 https://doaj.org/toc/1660-3397
remote_bool	true
author2	Don Johnson Brendan M. Duggan David A. Mead James J. La Clair
author2Str	Don Johnson Brendan M. Duggan David A. Mead James J. La Clair
ppnlink	477992420
callnumber-subject	QH - Natural History and Biology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/md21020056
callnumber-a	QH301-705.5
up_date	2024-07-03T13:29:26.471Z
_version_	1803564735861358592
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ080226639</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413062450.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230310s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/md21020056</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ080226639</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJef827ce5676c4de0a82d59de9de787c0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH301-705.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Robert J. Stankey</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em<</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">As one of the first families of marine natural products to undergo clinical trials, the didemnin depsipeptides have played a significant role in inspiring the discovery of marine drugs. Originally developed as anticancer therapeutics, the recent re-evaluation of these compounds including synthetically derived dehydrodidemnin B or Aplidine, has led to their advancement towards antiviral applications. While conventionally associated with production in colonial tunicates of the family <i<Didemnidae</i<, recent studies have identified their biosynthetic gene clusters from the marine–derived bacteria <i<Tistrella mobilis</i<. While these studies confirm the production of didemnin X/Y, the low titer and general lack of understanding of their biosynthesis in <i<Tistrella</i< currently prevents the development of effective microbial or synthetic biological approaches for their production. To this end, we conducted a survey of known species of <i<Tistrella</i< and report on their ability to produce the didemnin depsipeptides. These data were used to develop conditions to produce didemnin B at titers over 15 mg/L.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">didemnin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">depsipeptide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">non–ribosomal peptide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biosynthesis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">metabolomics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Biology (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Don Johnson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Brendan M. Duggan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David A. Mead</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">James J. La Clair</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Marine Drugs</subfield><subfield code="d">MDPI AG, 2005</subfield><subfield code="g">21(2023), 2, p 56</subfield><subfield code="w">(DE-627)477992420</subfield><subfield code="w">(DE-600)2175190-0</subfield><subfield code="x">16603397</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:21</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:2, p 56</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/md21020056</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ef827ce5676c4de0a82d59de9de787c0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/1660-3397/21/2/56</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1660-3397</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_381</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">21</subfield><subfield code="j">2023</subfield><subfield code="e">2, p 56</subfield></datafield></record></collection>
score	7.4010954

Nicht das Richtige dabei?

Schreiben Sie uns!

A Survey of Didemnin Depsipeptide Production in <em<Tistrella</em<

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?